Clinical trials: Psoriasis, completed
Psoriasis
Enstilar in Combination With Biologic Agents
Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
- Trial name
- NCT03080545
- Testing
- Enstilar 0.005%-0.064% Topical Foam
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
- Trial name
- NCT01245140
- Testing
- alitretinoin
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 33 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
A Study of SHR-1314 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single dose escalating, study in 5 sequential cohorts to investigate the effect of a single s.c.
- Trial name
- NCT02934412
- Testing
- SHR-1314
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Psoriasis
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
This study is an exploratory study to evaluate the effectiveness, safety and tolerability of three concentrations of GW786034 ointment following treatment to small areas of stable psoriatic plaques.
- Trial name
- NCT00358384
- Testing
- Pazopanib, Pazopanib vehicle, Betamethasone valerate
- Where
- France
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on…
- Trial name
- NCT02322086
- Testing
- Topical Rose Bengal, 0.005%
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Provectus Pharmaceuticals
Psoriasis
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque…
- Trial name
- NCT02564042
- Testing
- GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
- Where
- 46 sites in United States, Canada and 1 more
- Volunteers
- 227 people
- Sponsor
- GlaxoSmithKline
Psoriasis
Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis
Dithranol (known in the U.S.A. as anthralin and in Germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments.
- Trial name
- NCT02752672
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Quality of Life
Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus
This study is based on a survey about the patient centered care situation and health-related quality of life of patients with diagnoses Psoriasis, Urtikaria or Lupus erythematodes.
- Trial name
- PUL (NCT03324919)
- Testing
- HRQL
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- University Hospital Regensburg
Psoriasis
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are…
- Trial name
- PRIME (NCT02474082)
- Testing
- Secukinumab, Fumaric acid
- Where
- 32 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Vitamin D Deficiency
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors
Six-hundred subjects with vitamin D deficiency will be randomized to vitamin D 3000 IU per day versus placebo for 4 months, with effects on cardiovascular risk factors as main endpoint
- Trial name
- D-COR (NCT02750293)
- Testing
- Cholecalciferol
- Where
- Norway
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma
Psoriasis
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
This double-blind, placebo-controlled study will be conducted at 5 study centers in the United States. Approximately 30 subjects with moderate to severe plaque-type psoriasis will take part.
- Trial name
- NCT01154101
- Testing
- SRT2104
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sirtris, a GSK Company
Psoriasis, Inflammation
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular)…
- Trial name
- NCT02330380
- Testing
- Methotrexate, Ustekinumab, Etanercept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University Hospitals Cleveland Medical Center
Psoriasis
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
The purpose of the study is to compare the efficacy and safety of Clobetasol propionate to that of its Vehicle in the treatment of mild to moderate plaque-type psoriasis.
- Trial name
- NCT00842153
- Testing
- Clobetasol propionate foam, Vehicle foam
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Pediatric Plaque Psoriasis
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.
- Trial name
- NCT00141921
- Testing
- Etanercept
- Volunteers
- 182 people
- Sponsor
- Amgen
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
This study will compare how well adalimumab works versus methotrexate (MTX) in children with moderate to severe psoriasis in the short term.
- Trial name
- NCT01251614
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 114 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis, Spondyloarthritis
The NOR-SWITCH Study
The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Ulcerative Colitis
- Trial name
- NOR-SWITCH (NCT02148640)
- Testing
- Innovator infliximab, Biosimilar infliximab
- Where
- 30 sites in Norway
- Volunteers
- 482 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.
- Trial name
- NCT02772601
- Testing
- Caffeine, Warfarin, Omeprazole
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- AbbVie
Psoriasis
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4…
- Trial name
- NCT02397382
- Testing
- Guselkumab, Midazolam, Warfarin
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Janssen Research & Development, LLC